July 14, 2020
Weil advised investment firm bd-capital on its preliminary fundraise to acquire Symprove Holdings Limited, a manufacturer and distributor of food supplements. Launched to the public in 2010, Symprove is an innovative probiotic containing live, multi-strain bacteria, with a unique water-based delivery system which actively maintains gut health and the gut microbiome.
The fundraising was completed entirely “virtually” during the COVID-19 lockdown and attracted institutional investors from as far afield as the U.S. and Australia. Weil’s private funds and deal execution practices worked in seamless partnership with the bd-capital team to deliver on the transaction despite the backdrop of the ongoing global pandemic. This maiden deal marks a catalytic moment in the evolution of bd-capital – the investment firm set up in 2019 by former Whitbread Chairman Richard Baker and former investment partner at Advent International Andy Dawson.
The Weil team was led by Corporate partner Jonathan Wood and Private Funds partner James Bromley, and includes Corporate associates Kirstin Fyffe, Dominika Javornicka and Lottie Hudson; Private Funds counsel Marloes Zaman and associate Imaan Gangi; and Private Funds Tax partner Aron Joy and associate Daniella Abel.